Application Scenarios

Case Analysis

This study utilized single-cell transcriptome sequencing technology to analyze the high heterogeneity of the tumor microenvironment in prostate cancer. It identified micro-metastases that could not be detected by clinical pathology and imaging, and revealed how cancer cells manipulate the transcriptome of immune cells through exosomes, causing them to express tumor genes. These findings provide new insights for identifying therapeutic targets for prostate cancer and developing biomarkers for aggressive tumors.

Through ingenious experimental sample design, in-depth scRNA-Seq data analysis, and validation experiments, we elucidated the potential molecular mechanisms of lymph node metastasis in prostate cancer. We also discovered a new cell subtype associated with tumor progression, which holds significant implications for novel therapeutic strategies and prognosis guidance in prostate cancer.

NovelBio's tissue dissociator can rapidly and thoroughly dissociate various types of tissues into high-quality single-cell suspensions.

Microfluidics

In an independent water-in-oil environment, cells release RNA into gel microbeads. Nucleic acids carrying labels are amplified for library construction, followed by sequencing.

Micro-Wells

Cells naturally settle into individual micro-wells. An excess of magnetic beads are injected to fill the 200,000 micro-wells, ensuring that each cell in a well binds to a magnetic bead. Each well serves as an independent environment, enabling single-cell capture. Similarly, cells release RNA onto the magnetic beads, which are then amplified for library construction and sequenced.

Through fully automated processes and scaled production, NovelBio has significantly increased production capacity while reducing the cost of single-cell sequencing. Lowering costs without compromising quality—this is the true strength of NovelBio's innovation.